MaxCyte Inc (MXCT) - Total Liabilities
Based on the latest financial reports, MaxCyte Inc (MXCT) has total liabilities worth $33.20 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore MXCT cash flow metrics to assess how effectively this company generates cash.
MaxCyte Inc - Total Liabilities Trend (2012–2024)
This chart illustrates how MaxCyte Inc's total liabilities have evolved over time, based on quarterly financial data. Check MXCT asset resilience ratio to evaluate the company's liquid asset resilience ratio.
MaxCyte Inc Competitors by Total Liabilities
The table below lists competitors of MaxCyte Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Wellpool Co Ltd
TWO:8424
|
Taiwan | NT$181.62 Million |
|
Berenson Acquisition Corp I
NYSE MKT:BACA
|
USA | $27.33 Million |
|
Overseas Commerce Ltd
TA:OVRS
|
Israel | ILA446.32 Million |
|
Trek Metals Ltd
AU:TKM
|
Australia | AU$488.17K |
|
Union Auction Public Company Limited
BK:AUCT
|
Thailand | ฿1.31 Billion |
|
Sempio Foods Co
KO:248170
|
Korea | ₩132.99 Billion |
|
Say Yenilenebilir Enerji Ekipmanları Sanayi ve Ticaret Anonim Şirketi
IS:SAYAS
|
Turkey | TL844.16 Million |
|
Kingcan Holdings Ltd
TW:8411
|
Taiwan | NT$7.33 Billion |
Liability Composition Analysis (2012–2024)
This chart breaks down MaxCyte Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of MaxCyte Inc.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 7.74 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.18 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.16 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how MaxCyte Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for MaxCyte Inc (2012–2024)
The table below shows the annual total liabilities of MaxCyte Inc from 2012 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $33.22 Million | -8.00% |
| 2023-12-31 | $36.11 Million | +10.47% |
| 2022-12-31 | $32.69 Million | +54.01% |
| 2021-12-31 | $21.22 Million | +14.38% |
| 2020-12-31 | $18.55 Million | +13.25% |
| 2019-12-31 | $16.38 Million | +36.69% |
| 2018-12-31 | $11.99 Million | +1.57% |
| 2017-12-31 | $11.80 Million | +7.39% |
| 2016-12-31 | $10.99 Million | +15.87% |
| 2015-12-31 | $9.48 Million | +19.31% |
| 2014-12-31 | $7.95 Million | +96.37% |
| 2013-12-31 | $4.05 Million | +17.92% |
| 2012-12-31 | $3.43 Million | -- |
About MaxCyte Inc
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based … Read more